Drug intelligence / Profile preview

AH1206

Development stage: Unknown
Lead developer: Alimentary Health
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

AH1206 is a live biotherapeutic product consisting of a specific strain of the bacterium *Bifidobacterium longum*. Developed by Alimentary Health Ltd, it has been evaluated in clinical trials for the treatment of irritable bowel syndrome (IBS). The mechanism of action involves the modulation of the host's gut microbiota and the regulation of the mucosal immune system. Specifically, AH1206 is thought to promote an anti-inflammatory environment within the gastrointestinal tract by influencing cytokine production, such as increasing the levels of the anti-inflammatory cytokine interleukin-10 and potentially reducing pro-inflammatory markers like tumor necrosis factor. It was studied in a Phase 2, double-blind, randomized, placebo-controlled trial to assess its safety and efficacy in improving IBS symptoms in adult women, utilizing a 7-point Likert global improvement scale.

Other names: Bifidobacterium longum AH1206

Beyond the preview

Go deeper on AH1206.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AH1206.

Explore the full profile